Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

Mary Choy, PharmD, BCGP, FASHP  |  Issue: August 2019  |  August 16, 2019


Mary Choy, PharmD, BCGP, FASHP, is a medical writer and editor living in New York City. Dr. Choy is director of pharmacy practice at the New York State Council of Health-system Pharmacists.

References

  1. Singh JA, Saag KG, Bridges L, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016 Jan;68(1):1–26.
  2. Kim Y, Oh H, Park, J, et al. Diagnosis and treatment of inflammatory joint disease. Hip Pelvis. 2017 Dec;29(4):211–222.
  3. van Vilsteren MV, Boot CR, Knol DL, et al. Productivity at work and quality of life in patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2015 May;16:107.
  4. van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum. 1992 Jan:35(1):26–34.
  5. Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989 May;16(5):585–591.
  6. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017 June;389:2338–2348.
  7. Rheumatoid Arthritis Support Network. Rheumatoid arthritis resources.
  8. FDA website. Orencia prescribing information. 2017 Dec.
  9. FDA website. Humira prescribing information. 2018 Dec.
  10. FDA website. Amjevita prescribing information. 2018 Mar.
  11. FDA website. Cyltezo prescribing information. 2017 Aug.
  12. FDA website. Hyrimoz prescribing information. 2018 Oct.
  13. FDA website. Cimzia prescribing information. 2019 Feb.
  14. FDA website. Enbrel prescribing information. 2018 May.
  15. FDA website. Erelzi prescribing information. 2016 Aug.
  16. FDA website. Eticovo prescribing information. 2019 Apr.
  17. FDA website. Simponi prescribing information. 2011 Dec.
  18. FDA website. Simponi Aria prescribing information. 2018 Feb.
  19. FDA website. Remicade prescribing information. 2018 Jun.
  20. FDA website. Inflectra prescribing information. 2018 Jul.
  21. FDA website. Renflexis prescribing information. 2019 Mar.
  22. FDA website. Ixifi prescribing information. 2017 Dec.
  23. FDA website. Xeljanz prescribing information. 2018 May.
  24. Xeljanz label. Boxed warning (added July 2019). Pfizer Laboratories a division of Pfizer Inc.
  25. FDA website. Olumiant prescribing information. 2018 May.
  26. Olumiant. Select important safety information: Warning related to serious infections, malignancy, and thrombosis.
  27. FDA website. Rituximab prescribing information. 2019 Jan.
  28. FDA website. Kineret prescribing information. 2018 Jun.
  29. FDA website. Actemra prescribing information. 2019 Apr.
  30. FDA website. Kevzara prescribing information. 2018 Apr.

Page: 1 2 3 4 5 6 7 8 9 10 | Single Page
Share: 

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:abataceptadalimumabanakinrabaricitinibCertolizumab PegoletanerceptGolimumabinfliximabrituximabsarilumabtocilizumabTofacitinib

Related Articles
    kenary820 / shutterstock.com

    Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

    April 15, 2019

    Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    MicroOne / shutterstock.com

    Rheumatology Drugs at a Glance, Part 2: Psoriasis

    May 17, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    Andrew Brookes / Image Source on Offset

    Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5

    February 10, 2022

    Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    Psoriatic Arthritis Drugs at a Glance, 2023

    April 21, 2023

    Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences